173 related articles for article (PubMed ID: 35213039)
21. Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
Sánchez-Muñoz A; Ribelles N; Alba E
Clin Transl Oncol; 2010 Sep; 12(9):614-20. PubMed ID: 20851802
[TBL] [Abstract][Full Text] [Related]
22. By the way, doctor. I've had an ER-positive breast cancer tumor removed. Now I am getting ready for follow-up therapy. I've heard that the aromatase inhibitors are better than tamoxifen. What is your opinion?
Burnstein HJ
Harv Health Lett; 2008 May; 33(7):7. PubMed ID: 18700241
[No Abstract] [Full Text] [Related]
23. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
24. Aromatase inhibitors for breast cancer.
Briest S; Davidson NE
Rev Endocr Metab Disord; 2007 Sep; 8(3):215-28. PubMed ID: 17486453
[TBL] [Abstract][Full Text] [Related]
25. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
[No Abstract] [Full Text] [Related]
26. Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
O'Leary CG; Ellis H; Higgins M
Curr Opin Oncol; 2016 Nov; 28(6):455-460. PubMed ID: 27606696
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors in breast cancer: an overview.
Altundag K; Ibrahim NK
Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
[TBL] [Abstract][Full Text] [Related]
28. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
30. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Cianfrocca M; Wolff AC
Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitors: future directions.
Osborne CK; Schiff R
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):183-7. PubMed ID: 16019204
[TBL] [Abstract][Full Text] [Related]
32. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Vakaet L
J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
[No Abstract] [Full Text] [Related]
33. Adjuvant endocrine therapy in premenopausal women with breast cancer.
González Martín A; de la Cruz S; Márquez R
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
[No Abstract] [Full Text] [Related]
34. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
35. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
36. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Hayes DF; Stearns V; Rae J; Flockhart D;
J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
[No Abstract] [Full Text] [Related]
37. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A; Price KN; Gelber RD; ;
Clin Trials; 2009 Jun; 6(3):272-87. PubMed ID: 19528136
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor-positive (ER
Ferreira Almeida C; Oliveira A; João Ramos M; Fernandes PA; Teixeira N; Amaral C
Biochem Pharmacol; 2020 Jul; 177():113989. PubMed ID: 32330493
[TBL] [Abstract][Full Text] [Related]
39. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
40. Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.
Bense RD; Qiu SQ; de Vries EGE; Schröder CP; Fehrmann RSN
Cancer Treat Rev; 2018 Nov; 70():118-126. PubMed ID: 30149225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]